Montserrat Arnan

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Erratum for Laporte-Amargos et al., "Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia".

Erratum for Laporte-Amargos et al., "Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia".

Journal: Antimicrobial agents and chemotherapy
Published: July 15, 2026

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

Journal: The New England journal of medicine
Published: June 03, 2026

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

Journal: American journal of hematology
Published: April 24, 2026

Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia.

Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia.

Journal: Antimicrobial agents and chemotherapy
Published: November 25, 2025

Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes.

Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: October 22, 2025

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Journal: Annals of hematology
Published: April 09, 2025

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Journal: Blood cancer journal
Published: February 11, 2025

Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols.

Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols.

Journal: Medicina clinica
Published: January 24, 2025

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Journal: Experimental hematology & oncology
Published: December 26, 2024

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

Journal: Cancers
Published: October 27, 2024

CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.

CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.

Journal: Diagnostic pathology
Published: October 22, 2024

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Journal: Blood cancer journal
Published: October 17, 2024
Showing 1-12 of 76

Last Updated: 09/26/2026